Evidence map›Paper›PMID 24076556›Full record

ReviewCurrent opinion in nephrology and hypertension2013

New models of chronic kidney disease care including pharmacists: improving medication reconciliation and medication management.

Wendy L St Peter, Lori D Wazny, Uptal D Patel

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in nephrology and hypertension, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Effect of pharmacist interventions in chronic kidney disease: a meta-analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Diabetic Kidney Disease Prevention Care Model Development.Clinical diabetes : a publication of the American Diabetes Association · 2024
    Article
  10. Article
  11. Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2023
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Wendy L St PeteraChronic Disease Research Group, Minneapolis Medical Research Foundation bCollege of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA cManitoba Renal Program dWinnipeg Regional Health Authority Pharmacy Program, Winnipeg, Manitoba, Canada eDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Lori D Wazny
Uptal D Patel
Duke Medical Center · USManitoba Health · CAUniversity of Minnesota System · US

Funding

Multi-factorial Intervention to Slow Progression of Diabetic Kidney DiseaseR01DK093938 · NIDDK · DUKE UNIVERSITY · PI BOSWORTH, HAYDEN B, DIAMANTIDIS, CLARISSA JONAS · 2013 to 2017
$3.4M
NIDDK NIH HHS R01 DK093938
6 · The paper itself

Abstract

purpose of reviewPatients with chronic kidney disease (CKD) are complex, have many medication-related problems (MRPs) and high rates of medication nonadherence, and are less adherent to some medications than patients with higher levels of kidney function. Nonadherence in CKD patients increases the odds of uncontrolled hypertension, which can increase the risk of CKD progression. This review discusses reasons for gaps in medication-related care for CKD patients, pharmacy services to reduce these gaps and successful models that incorporate pharmacist care. RECENT

findingsPharmacists are currently being trained to deliver patient-centred care, including identification and management of MRPs and helping patients overcome barriers to improve medication adherence. A growing body of evidence indicates that pharmacist services for CKD patients, including medication reconciliation and medication therapy management, positively affect clinical and cost outcomes, including lower rates of decline in glomerular filtration rates, reduced mortality and fewer hospitalizations and hospital days, but more robust research is needed. Team-based models including pharmacists exist today and are being studied in a wide range of innovative care and reimbursement models. SUMMARY: Opportunities are growing to include pharmacists as integral members of CKD and dialysis healthcare teams to reduce MRPs, increase medication adherence and improve patient outcomes.

Indexed as

Patient Care TeamPharmacistsHumansMedication AdherenceMedication ReconciliationModels, OrganizationalRenal Insufficiency, Chronic

Identifiers

PMID24076556
PMCPMC4012859
OpenAlexW2005555384

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.